Acticor Biotech SA
PAR:ALACT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acticor Biotech SA
Income from Continuing Operations
Acticor Biotech SA
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acticor Biotech SA
PAR:ALACT
|
Income from Continuing Operations
-€18.6m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Income from Continuing Operations
-€115.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-19%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Income from Continuing Operations
-€86m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-18%
|
|
|
Inventiva SA
PAR:IVA
|
Income from Continuing Operations
-€353.8m
|
CAGR 3-Years
-87%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Income from Continuing Operations
-$147.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-13%
|
|
|
Abivax SA
PAR:ABVX
|
Income from Continuing Operations
-€336.1m
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
Acticor Biotech SA
Glance View
Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2021-11-01. The firm is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.
See Also
What is Acticor Biotech SA's Income from Continuing Operations?
Income from Continuing Operations
-18.6m
EUR
Based on the financial report for Dec 31, 2023, Acticor Biotech SA's Income from Continuing Operations amounts to -18.6m EUR.
What is Acticor Biotech SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-26%
Over the last year, the Income from Continuing Operations growth was -17%. The average annual Income from Continuing Operations growth rates for Acticor Biotech SA have been -35% over the past three years , -26% over the past five years .
